In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMimetic grosses $8mm via private financing

Executive Summary

Orthopedics company BioMimetic Therapeutics grossed $8mm through the private placement of 941,177 common shares at $8.50 each (a 9% premium) to InterWest Partners. Concurrently the company announced plans to commence a rights offering of up to $17mm, in which current investor Novo AS will buy as much as $15mm in common stock (at $8.50 per share) if other existing shareholders do not participate.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies